Cullinan Oncology closes $275M sale of Cullinan Pearl to Taiho; co-development deal for CLN-081

Cullinan Therapeutics, Inc.

Upfront cash payment of $275M from Taiho; potential $130M in regulatory milestones for CLN-081/TAS6417.
Taiho obtains exclusive global rights outside U.S.; companies co-develop and co-commercialize CLN-081 in U.S.
U.S. profits and development costs split 50/50 between Cullinan and Taiho; Cullinan retains co-commercialization option.
Deal includes sale of Cullinan Pearl Corp., which holds ex-Japan rights to CLN-081/TAS6417.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.